98%
921
2 minutes
20
Cerebrospinal fluid (CSF) rhinorrhea is a rare and unexpected initial presentation of untreated invasive pituitary macroprolactinoma. This article aims to better understand the management of invasive pituitary macroprolactinoma, especially in cases where the patient initially presents with a CSF leak. We describe a case of a 36-year-old male with untreated invasive macroprolactinoma with a CSF leak at the initial presentation. The role and timing of medical and surgical treatment in such a setting are outlined in detail. Medical therapy has shown both worsening and resolution of the CSF leak. We propose a ''Sandwich Therapy'' in Dopamine agonist (DA) responsive cases where the leak persists, which includes initial DA therapy, followed by endoscopic Transsphenoidal surgery (TSS) with DA therapy and then followed by the post-operative continuation of DA therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985827 | PMC |
http://dx.doi.org/10.1007/s12070-025-05406-7 | DOI Listing |
Genet Test Mol Biomarkers
September 2025
Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Male patients with prolactinomas exhibit greater invasiveness, resistance to dopamine agonists, making treatment more challenging. This study aims to explore the potential different genes contributing to sex disparities in prolactinomas. Weighted gene co-expression network analysis and differential expressed genes analysis were performed to identify sex-related hub genes.
View Article and Find Full Text PDFIntroduction: Invasive fungal infection (IFI) after chimeric antigen receptor (CAR) T-cell therapy is less common than bacterial and viral infections, but can be fatal once it develops. As most cases occur within 30 days after CAR T-cell infusion, late-onset IFI-particularly mould infection-appears to be under-recognised.
Discussion: We report an illustrative case of pituitary aspergillosis developing as late as one year after CD19 CAR T-cell therapy, highlighting a persistent risk in certain patients with delayed immune reconstitution.
Brain Tumor Pathol
September 2025
Hypothalamic Pituitary Center, Moriyama Memorial Hospital, Tokyo, Japan.
Pituitary neuroendocrine tumors (PitNETs) are generally benign, but a small subset may demonstrate aggressive behavior or undergo malignant transformation. Neuroendocrine carcinoma (NEC), defined as a high-grade, poorly differentiated neuroendocrine neoplasm, is extremely rare in the pituitary, and its existence as a primary entity remains controversial. We report two cases of corticotroph PitNETs in female patients with Cushing disease, in which NEC components emerged several years after radiotherapy.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Endocrinology and Internal Medicine, Medical College, Andrzej Frycz Modrzewski Krakow University, 30-705 Kraków, Poland.
Pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas, are rare tumors that are usually benign. At present, the WHO PitNET classification based on transcription factors is in force. A problem is caused by invasive tumors and silent tumors which, despite a lack of obvious clinical symptoms, tend to behave aggressively.
View Article and Find Full Text PDFNeurosurgery
August 2025
Neurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland, USA.
Background And Objectives: Unrecognized cavernous sinus (CS) invasion by adenomas is a major factor in surgical failure and recurrence of Cushing disease (CD), and pituitary adenomas. Exploration of the CS during trans-sphenoidal surgery (TSS) and resection of the involved medial wall of CS (medial wall of the CS) can achieve apparent gross total resection. However, novel strategies are needed to identify patients with occult tumor residuals and direct them to early radiotherapy.
View Article and Find Full Text PDF